|1.||Lyman, Gary H: 27 articles (08/2015 - 09/2002)|
|2.||Crawford, Jeffrey: 12 articles (01/2015 - 08/2003)|
|3.||Dale, David C: 9 articles (01/2015 - 01/2002)|
|4.||Bennett, Charles L: 6 articles (07/2013 - 09/2002)|
|5.||Du, Xianglin L: 5 articles (01/2016 - 10/2010)|
|6.||Li, Xiaoyan: 5 articles (08/2015 - 01/2013)|
|7.||Malin, Jennifer: 5 articles (06/2012 - 05/2007)|
|8.||Kuderer, Nicole M: 5 articles (06/2011 - 10/2003)|
|9.||Dygai, A M: 5 articles (09/2009 - 03/2005)|
|10.||Zhdanov, V V: 5 articles (09/2009 - 03/2005)|
06/01/1996 - "As mentioned previously, the use of colony-stimulating factors has dramatically improved the outcome for many patients with the more severe neutropenia; however, this cytokine is expensive, so treatment should be reserved for more severely affected patients and not given just because the ANC is low. "
01/01/1996 - "The number of patients who recovered from severe neutropenia ( < 100 cells/microliter) during the period of observation in the study was significantly greater among patients receiving the colony-stimulating factor, although the median duration of neutropenia was not affected. "
07/01/2006 - "When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?"
07/01/2007 - "A relevant body of scientific evidence has been produced in the last 2 decades, through clinical trials addressing the efficacy of colony stimulating factors (CSFs) in the prevention and treatment of febrile neutropenia. "
12/01/2008 - "In the past decade, there have been many clinical trials investigating the potential benefits of adjunctive therapy with colony stimulating factors (CSFs) both to ameliorate or prevent profound neutropenia and its potentially life threatening consequences. "
10/01/2009 - "The widespread use of hematopoietic colony-stimulating factors, as well as the development of new agents, has led to improved outcomes in many types of cancer. "
05/01/2006 - "The purpose of this analysis was to examine the efficacy of prophylactic hematopoietic colony-stimulating factors (CSFs) in pediatric cancer and to describe how a Bayesian meta-analysis can be conducted and then modified to incorporate information not readily included in a frequentist meta-analysis. "
01/01/1990 - "Towards improved cancer therapy using subcutaneously administered hemopoietic colony stimulating factors."
03/01/2013 - "Our study uncovers a novel, chemokine-independent activity of the hematopoietically derived CCL5 that promotes mammary tumor progression via generating MDSCs in the bone marrow in cooperation with tumor-derived colony-stimulating factors. "
07/01/2001 - "The purpose of this study was to assess the impact of the American Society of Clinical Oncology (ASCO) guidelines regarding use of hematopoietic colony-stimulating factors (CSF) on cancer care in a university hospital in Paris. "
06/01/2005 - "Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients."
01/01/1998 - "This study examined the determinants of compliance with clinical guidelines for glucocyte colony-stimulating factor (GCSF), a biotechnology product designed to reduce postchemotherapy infections. "
01/01/1994 - "Data on the role of colony-stimulating factors against fungal pathogens are accumulating, and trials with these agents for hematologic patients with invasive fungal infections are now being performed."
07/01/1984 - "In this study, the concentrations of colony stimulating factor (CSF) and the numbers of monocyte progenitor cells (CFUm) were measured in mice during infection with L. "
09/18/2007 - "Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection."
|4.||Breast Neoplasms (Breast Cancer)
06/15/2004 - "A number of recent studies have suggested that the colony-stimulating factor (CSF-1) and its receptor c-fms may be involved in the development of mammary glands during lactation and breast cancer. "
01/01/2002 - "Combined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel+granulocyte colony stimulating factor."
06/01/2014 - "Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors."
03/10/2012 - "Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer."
02/01/2005 - "Further studies are needed to adequately evaluate the risk of neutropenic complications (NC) in elderly patients receiving standard-dose chemotherapy for breast cancer and the potential benefits of primary prophylaxis with colony-stimulating factors."
09/01/2005 - "Emphasis is laid on a role of colony-stimulating factors in the correction of agranulocytosis. "
01/01/2004 - "Granulocyte colony-stimulating factors was employed to ameliorate severe granulocytopenia. "
01/01/2000 - "Use of colony-stimulating factors for the treatment of antithyroid drug-induced agranulocytosis: a retrospective study in twelve patients."
03/01/1999 - "Nonchemotherapy drug-induced agranulocytosis: a review of 118 patients treated with colony-stimulating factors."
09/01/1998 - "Use of recombinant human hemopoietic colony-stimulating factor was reported to be of benefit in patients who developed agranulocytosis, although there is still some doubt regarding the efficacy in AA. "
|1.||Granulocyte Colony-Stimulating Factor (G-CSF)
|2.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|9.||Macrophage Colony-Stimulating Factor
|1.||Drug Therapy (Chemotherapy)
|2.||Transplantation (Transplant Recipients)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)